Direct compression of anisodamine hydrobromide tablets: formulation boundaries and ejection force data

Direct compression of anisodamine hydrobromide veterinary tablets is constrained by the low unit dose of a water-soluble ester alkaloid. Published production-scale data for this specific API configuration are limited, but established practice for low-dose antimuscarinic hydrobromides indicates that the API should pass through a 60 mesh screen to achieve a particle size below 250 µm before blending. Pre-dispersion with microcrystalline cellulose PH102 or lactose monohydrate at 1:10 w/w in a high-shear mixer for 5–8 minutes at 25 rpm reduces electrostatic agglomeration and prevents the active from segregating in the hopper. Main blending is then performed in a bin blender at 10–12 rpm for 15 minutes, followed by the addition of 0.5% w/w magnesium stearate and additional blending for 3–5 minutes. Blend uniformity is sampled at 10 positions under 21 CFR 211.110 and evaluated against USP <905> with an acceptance value not exceeding 15. Compression is run on a rotary tablet press with 8 mm round flat-faced bevel-edge punches. Main compression force is typically adjusted between 10 kN and 20 kN to achieve tablet hardness from 50 N to 80 N, while ejection force is kept below 1.5 kN to avoid picking and sticking. Tablet friability is expected to remain ≤1.0% w/w when tested by USP <1216>. Because the hydrobromide salt is moisture-sensitive under prolonged humid exposure, bulk tablet granulation should not be stored outside open containers; pre-drying at 40 °C in a vacuum tray dryer until loss on drying is ≤0.5% w/w is recommended when ambient relative humidity exceeds 60%. Over-lubrication should be avoided because prolonged blending with magnesium stearate from 7 minutes onward can retard disintegration and dissolution of the finished tablet.

Equipment surfaces for tablet manufacture must comply with 21 CFR 211.65, requiring non-reactive contact surfaces. The use of 316L stainless steel for blender walls, tablet press dies, and punches is accepted in veterinary pharmaceutical production. Compression room humidity is typically controlled at 40–50% RH and 21–23 °C to prevent water uptake by the API and to maintain consistent powder flow. In-process tablet weight variation is checked every 30 minutes and hardness is tested every 60 minutes during the batch. Direct compression is preferred only when the API lot demonstrates acceptable flowability; if the Carr’s index exceeds 25 or the Hausner ratio exceeds 1.25, dry granulation should be selected instead. Dissolution testing of the finished tablet, where required by the sponsor specification, follows USP <711> using an apparatus suitable for immediate-release veterinary tablets.

Why would terminal moist heat sterilization alter anisodamine hydrobromide injection pH?

Terminal moist heat sterilization of anisodamine hydrobromide injection can alter pH and generate hydrolytic degradation products because the API contains an ester group on the tropane backbone. Aqueous solutions are prepared in 316L stainless steel tanks with surface finish Ra ≤0.6 µm under 21 CFR 211.65. The solution is adjusted to a mildly acidic pH range, most commonly 4.5–6.0, with dilute hydrochloric acid or sodium hydroxide; published pharmacopoeial pH specifications for veterinary anisodamine hydrobromide injection are limited and must be established by stability-indicating studies. Water for injection is used as the vehicle and must meet conductivity, total organic carbon, and microbial limits of the current pharmacopoeia. The filled solution is sterilized at 121 °C for 15 minutes, giving an F0 value of 15 minutes, only if heat-penetration studies and assay-degradation profiles confirm that the ester hydrolysis rate is acceptable at this exposure. If not, aseptic filtration through a 0.22 µm sterilizing-grade membrane into depyrogenated Type I borosilicate glass vials conforming to Ph. Eur. 3.2.1 is selected. Filling areas for terminal sterilization are classified as ISO 14644-1 Class 7; aseptic filling requires ISO 14644-1 Class 5 in the critical zone. Container integrity testing after vial sealing or ampoule pulling is required to prevent oxygen ingress and microbial contamination.

Because the hydrobromide salt is water-soluble, filter adsorption must be validated during aseptic processing. Some nylon or polyethersulfone membranes may retain low concentrations of the active under specific ionic strength conditions. Sterility testing is performed per Ph. Eur. 5.1.1 or USP <71>, while bacterial endotoxin testing follows Ph. Eur. 2.6.14 or USP <85> using limits defined by the target species and route of administration. Sub-visible particulate matter is controlled by Ph. Eur. 2.9.19 or USP <788>. Stoppers and seals are evaluated for extractables and leachables, particularly after terminal steam sterilization, because elastomer breakdown products can react with anisodamine hydrobromide under acidic conditions. No antioxidant should be added without forced degradation support, and the addition of sodium metabisulfite is not automatically required for this API. The final injection product should be protected from light only if photostability testing under VICH GL6 demonstrates ultraviolet sensitivity.

Automatic capsule filling of low-dose anisodamine hydrobromide is sensitive to equilibrium moisture content in the powder blend because hydrobromide salts can become tacky when exposed to relative humidity above 50%. The capsule filling corridor is therefore maintained at 35–45% RH and 21–23 °C. The pre-blend is composed of anhydrous lactose monohydrate, microcrystalline cellulose PH102, and croscarmellose sodium at 2.0% w/w; the API is introduced as a 1:10 starch or lactose triturate to prevent potency hotspots. Ribbon blending of the main mass is performed for 20 minutes at 25 rpm in a 300–600 L bin blender. Magnesium stearate is added at 0.5% w/w and blended for no more than 4 minutes to limit hydrophobic surface coating. If gelatin capsules are used, shell moisture content is maintained at 13–16% w/w to prevent embrittlement or shell softening. HPMC capsules are an alternative for non-animal-derived markets and typically require lower filling room humidity but are less hygroscopic than gelatin.

Tamping pin capsule fillers achieve fill weight RSD ≤2.0% at speeds up to 80,000 capsules/hour, although published data for anisodamine hydrobromide at this throughput are limited. In-process weight checks are performed every 30 minutes under 21 CFR 211.110. Uniformity of dosage units is assessed by USP <905> using an acceptance value ≤15. Because the API is water-soluble, dissolution from capsules is usually dependent on disintegrant performance rather than drug solubility. Disintegration testing is performed under current pharmacopoeial methods. Cross-contamination control is critical because the API is active at low dose; validated cleaning procedures with swab limits derived from toxicological data must be implemented. Capsule filling lines should not be used for multiple potent alkaloid preparations without dedicated or thoroughly validated changeover programs.

Roller-Compacted Granulations Without Binder Solution

For low-dose anisodamine hydrobromide tablets or capsules, aqueous wet granulation is often avoided because the salt is water-soluble and the ester alkaloid can migrate to granule surfaces during drying. Dry granulation through roller compaction is therefore selected when direct compression is not robust. The pre-blend contains API, microcrystalline cellulose PH102, crospovidone at 2.0% w/w, and colloidal silicon dioxide at 0.2% w/w. Roller compaction is run at hydraulic roll pressure from 80 bar to 120 bar, roll gap from 2 mm to 3 mm, and roll speed from 5 rpm to 10 rpm. These values are typical for low-density pharmaceutical powders but must be qualified for each API lot because particle size and residual moisture change compaction behavior. The compacted ribbons are milled through a 1.0 mm screen, and the granulation is classified to retain particles between 125 µm and 850 µm. Fines below 125 µm can segregate during compression, while coarse particles above 850 µm increase weight variation.

Granule moisture is maintained at ≤1.0% w/w by USP <731>. Higher moisture can promote sticking to punch faces and reduce powder flow. Final lubrication is performed with 0.5% w/w magnesium stearate for 3–5 minutes in a V-blender. Powder flow should demonstrate a Carr’s index ≤25 and Hausner ratio ≤1.25. If aqueous wet granulation is unavoidable, the binder solution must be applied in a high-shear granulator at low water quantity, and the wet mass must be dried rapidly in a fluid bed at 50–60 °C inlet air until loss on drying is ≤2.0% w/w. Near-infrared moisture probes should be used to stop drying before the ester-containing API hydrolyzes. Published data for anisodamine hydrobromide wet granulation at production scale are limited; pilot-scale trials are required before commercial batches are committed.

Oral powder sachets containing anisodamine hydrobromide for individual animal dosing require a free-flowing formulation that can be weighed separately and mixed with a small quantity of feed or water at the point of administration. The powder is prepared as a triturate of API with lactose monohydrate and precipitated calcium carbonate as a carrier; colloidal silicon dioxide is added at 0.3–0.5% w/w to improve flow and reduce caking during storage. Mixing is performed in a 500–1,000 L ribbon blender for 15–20 minutes at 25 rpm. Blend uniformity is tested at 10 sampling points using a validated HPLC assay, with acceptance as a relative standard deviation ≤5.0%. Sachet filling is performed on vertical form-fill-seal equipment with heat-sealed foil-laminated film having a water vapor transmission rate below 0.1 g/m²/day per ASTM F1249. The moisture barrier prevents clumping and hydrolysis of the hydrobromide powder.

In-use preparation at the farm may involve sprinkling the powder onto a small amount of moist feed or dispersing in water at 20–25 °C. Because the API is water-soluble, immediate dissolution is expected in water, but alkaline farm water above pH 8.0 can accelerate hydrolysis of the ester linkage. Operators should check water pH before dispersion and use a buffer if necessary. The prepared suspension should be administered within 24 hours unless in-use stability data support longer hold times. Residual solvent control follows VICH GL18, with limits applied to any ethanol or isopropanol used during API recrystallization. Stability testing for the sachet product follows VICH GL49 using long-term storage conditions of 25 °C/60% RH or 30 °C/75% RH depending on the target region. Batch-to-batch variation in carrier bulk density and API particle size must be evaluated during process validation to prevent segregation and inconsistent dosing.

Feed premix homogeneity in high-speed horizontal mixers

Anisodamine hydrobromide premixes intended for drinking water or feed incorporation are often manufactured as free-flowing, water-dispersible preparations rather than concentrated API blends. The carrier system is typically lactose monohydrate, dextrose monohydrate, or corn starch, with sodium chloride as a density modifier. Colloidal silicon dioxide is included at 0.3–0.5% w/w to improve flow. Geometric dilution of the API is performed before charging into a horizontal ribbon mixer of 1,000–2,000 L working volume. Mixing proceeds for 20 minutes at 25 rpm. Homogeneity is determined by sampling at 10 points and assaying for active content; the coefficient of variation should be ≤5.0%. The final premix is packaged in heat-sealed laminated foil bags with a moisture barrier below 0.1 g/m²/day per ASTM F1249 to prevent moisture uptake and clumping.

At the point of use, the premix is metered into drinking water through a proportioner. The hydrobromide salt is expected to dissolve rapidly at 20–25 °C, but hard water with high carbonate alkalinity can raise pH above 8.0 and accelerate ester hydrolysis. The operator should measure pH before administration and use a buffering agent if the pH exceeds 8.0. Medicated water should be consumed within 24 hours and should not be stored under direct sunlight. Residual solvent levels in the premix must comply with VICH GL18. Stability testing for the premix follows VICH GL49 at long-term conditions appropriate to the target region. Process validation must demonstrate that the active does not segregate during discharge or packaging, and cleaning validation must cover the next product because anisodamine hydrobromide is potent at low concentrations.

If a multi-dose oral solution is selected, preservative and pH control become critical variables

Multi-dose veterinary oral solutions of anisodamine hydrobromide require antimicrobial preservation effectiveness demonstrated by USP <51> or Ph. Eur. 5.1.3. The solution is compounded in a 316L stainless steel tank with a bottom-mounted impeller operating at 150–300 rpm. Anisodamine hydrobromide is dissolved in Purified Water at 20–25 °C, and the pH is adjusted with a citrate or phosphate buffer to the mildly acidic range, typically 4.5–5.5, if stability data support that target. The ester linkage is hydrolyzed under alkaline conditions, so neutral or alkaline pH should be avoided unless accelerated studies demonstrate acceptable stability. The batch is filtered through a 0.45 µm polymeric membrane to remove undissolved particles. Filter material must be tested for API adsorption because a water-soluble hydrobromide salt may bind to nylon or polyethersulfone membranes under certain ionic strength conditions.

The filtered solution is filled into light-protective polyethylene terephthalate bottles if photostability testing under VICH GL6 shows sensitivity to ultraviolet light. Closure systems should include tamper-evident features and child-resistant components under 21 CFR 211.132 where applicable. Storage at 2–8 °C is common for unpreserved oral solutions; preserved multi-dose solutions may be stored at controlled room temperature only if stability data under 30 °C/75% RH support assignment. In-use stability testing after first opening should simulate repeated broaching and dosing over the intended treatment period. If precipitation, pH drift, or microbial outgrowth occurs, the product must be rejected. Because no published veterinary-specific stability database for anisodamine hydrobromide oral solutions at production scale exists, each formulation requires a bracketing study covering pH, oxygen headspace, closure system, and preservative concentration.